logo

Journals Books
Advanced Search
Sign in Register

中文

SCIENCE CHINA Chemistry
Download PDF
SCIENCE CHINA Chemistry, Volume 61, Issue 4: 497-504(2018) https://doi.org/10.1007/s11426-017-9176-3

Engineering a customized nanodrug delivery system at the cellular level for targeted cancer therapy

Jin Li1, Liping Qiu1,*, Sitao Xie1, Jing Zhang1, Liqin Zhang1,2, Honglin Liu1, Juan Li3, Xiaobing Zhang1, Weihong Tan1,2,*
More info
  • ReceivedSep 27, 2017
  • AcceptedNov 13, 2017
  • PublishedJan 11, 2018
Previous Table of Contents Next
Share
Rating

Abstract

Drug administration customized to individual cells could intrinsically address cancer heterogeneity and provide a safe and effective method for delivering personalized treatment. To accomplish this, we developed a smart nanodrug delivery system characterized by cancer cell-targeted drug delivery and intracellular biomarker-responsive drug activation. This system was composed of a long-nicked DNA duplex formed by tandem hybridization of two extended antisense oligonucleotides whose ends were separately blocked with a cancer cell-specific aptamer, AS1411, and a replaceable anti-biomarker probe (ABP). We demonstrated that this DNA nanodrug was directed to cancer cells with the guidance power of AS1411 and then activated by the presence of a given intracellular biomarker. By using such a belt-and-braces strategy, this DNA nanodrug system could safely and efficiently accelerate apoptosis of target cancer cells. Moreover, since the expression level of biomarkers tends to indicate the specific physiological state of individual cells, biomarker-responsive activation of the nanodrug is expected to enable customized drug administration at the cellular level.


Funded by

the National Natural Science Foundation of China(21505039,2013CB932702)

the China National Instrumentation Program(2011YQ03012412)

the National Institutes of Health grants(GM079359,CA133086)


Acknowledgment

This work was supported by the National Natural Science Foundation of China (21505039, 2013CB932702), the China National Instrumentation Program (2011YQ03012412) and the National Institutes of Health grants (GM079359, CA133086).


Interest statement

The authors declare that they have no conflict of interest.


Supplement

The supporting information is available online at http://chem.scichina.com and http://link.springer.com/journal/11426. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


References

[1] Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. Nature, 2011, 470: 214-220 CrossRef PubMed ADS Google Scholar

[2] Sander C. Science, 2000, 287: 1977-1978 CrossRef Google Scholar

[3] Almendro V, Marusyk A, Polyak K. Annu Rev Pathol Mech Dis, 2013, 8: 277-302 CrossRef PubMed Google Scholar

[4] Niidome T, Huang L. Gene Ther, 2002, 9: 1647-1652 CrossRef PubMed Google Scholar

[5] Stegh AH. Integr Biol, 2013, 5: 48-65 CrossRef PubMed Google Scholar

[6] Wang L, Zhang H, Qin A, Jin Q, Tang BZ, Ji J. Sci China Chem, 2016, 59: 1609-1615 CrossRef Google Scholar

[7] Xu C, Tian H, Chen X. Sci China Chem, 2017, 60: 319-328 CrossRef Google Scholar

[8] Jia H, Chen S, Zhuo R, Feng J, Zhang X. Sci China Chem, 2016, 59: 1397-1404 CrossRef Google Scholar

[9] Pinheiro AV, Han D, Shih WM, Yan H. Nat Nanotech, 2011, 6: 763-772 CrossRef PubMed ADS Google Scholar

[10] Fang X, Tan W. Acc Chem Res, 2009, 43: 48-57 CrossRef PubMed Google Scholar

[11] Chang YT, Liao PY, Sheu HS, Tseng YJ, Cheng FY, Yeh CS. Adv Mater, 2012, 24: 3309-3314 CrossRef PubMed Google Scholar

[12] Dicheva BM, ten Hagen TLM, Li L, Schipper D, Seynhaeve ALB, van Rhoon GC, Eggermont AMM, Lindner LH, Koning GA. Nano Lett, 2012, 13: 2324-2331 CrossRef PubMed ADS Google Scholar

[13] Lee JH, Chen KJ, Noh SH, Garcia MA, Wang H, Lin WY, Jeong H, Kong BJ, Stout DB, Cheon J, Tseng HR. Angew Chem, 2013, 125: 4480-4484 CrossRef Google Scholar

[14] Huebsch N, Kearney CJ, Zhao X, Kim J, Cezar CA, Suo Z, Mooney DJ. Proc Natl Acad Sci USA, 2014, 111: 9762-9767 CrossRef PubMed ADS Google Scholar

[15] Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S. Nat Commun, 2013, 4: 1707 CrossRef PubMed ADS Google Scholar

[16] Mura S, Nicolas J, Couvreur P. Nat Mater, 2013, 12: 991-1003 CrossRef PubMed ADS Google Scholar

[17] Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. J Control Release, 2011, 152: 2-12 CrossRef PubMed Google Scholar

[18] Zhang X, Yang P, Dai Y, Ma P, Li X, Cheng Z, Hou Z, Kang X, Li C, Lin J. Adv Funct Mater, 2013, 23: 4067-4078 CrossRef Google Scholar

[19] Xing L, Zheng H, Cao Y, Che S. Adv Mater, 2012, 24: 6433-6437 CrossRef PubMed Google Scholar

[20] Chung MF, Chia WT, Wan WL, Lin YJ, Sung HW. J Am Chem Soc, 2015, 137: 12462-12465 CrossRef PubMed Google Scholar

[21] Zhang DY, Seelig G. Nat Chem, 2011, 3: 103-113 CrossRef ADS Google Scholar

[22] Ireson C, Green C, Cook J, Djeha H, Ritchie C, Jones D, Kelland LR. Cancer Res, 20066611071108. Google Scholar

[23] Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. Oncogene, 2007, 26: 2799-2803 CrossRef PubMed Google Scholar

[24] Wang PY, Li YJ, Zhang S, Li ZL, Yue Z, Xie N, Xie SY. Mol Cell Biochem, 2010, 339: 163-171 CrossRef PubMed Google Scholar

[25] Cheng AM, Byrom MW, Shelton J, Ford LP. Nucleic Acids Res, 2005, 33: 1290-1297 CrossRef PubMed Google Scholar

[26] Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z. Biomaterials, 2014, 35: 3840-3850 CrossRef PubMed Google Scholar

[27] Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Nat Med, 1996, 2: 668-675 CrossRef Google Scholar

[28] Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C, Tan W. Proc Natl Acad Sci USA, 2013, 110: 7998-8003 CrossRef PubMed ADS Google Scholar

[29] Kesharwani P, Gajbhiye V, Jain NK. Biomaterials, 2012, 33: 7138-7150 CrossRef PubMed Google Scholar

[30] Reyes-Reyes EM, Teng Y, Bates PJ. Cancer Res, 2010, 70: 8617-8629 CrossRef PubMed Google Scholar

[31] Zhang J, Wang J, Zhao F, Liu Q, Jiang K, Yang G. Clinica Chim Acta, 2010, 411: 846-852 CrossRef PubMed Google Scholar

[32] Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, Jiang X, Wang C, Zhang J, Zen K, Zhang CY, Chen X. Eur J Cancer, 2014, 50: 1013-1024 CrossRef PubMed Google Scholar

  • Click to view Download high-quality image

    Figure 1

    (a) Formation of nanodrugs characterized by atomic force microscope (AFM); (b) biomarker-responsive dissociation of the Apt-ND-ABP confirmed with 1.5% agarose gel electrophoresis. From Lanes 1 to 5: Apt-ND-ABP; Apt-ND-ABP+TA+TB; Apt-ND-ABP+TA+TB+BM; Apt-ND-rd; Apt-ND-rd+TA+TB+BM. Each sample was incubated at 37 °C for 1 h and then analyzed by agarose gel electrophoresis. The concentrations of A, B, TA, TB and BM were all fixed at 1 µM (color online).

  • Click to view Download high-quality image

    Scheme 1

    Schematic illustration of the biomarker-responsive nanodrug delivery system for targeted cancer therapy at the cellular level. Apt-ND-ABP is composed of the nanodrug with two ends separately blocked with aptamer AS1411 and Anti-biomarker probe ABP. Apt-ND-ABP passes through the cell membrane guided by AS1411. In the absence of biomarker/ABP interaction, the nanodrug is quiescent. However, upon sensing the biomarker as an indicator of the specific physiological state of individual cells, ABP is removed by formation of a biomarker/ABP complex, followed by exposure of the nanodrug toehold for access to therapeutic target miRNAs (miRNA-21 and miRNA-150) for cell apoptosis (color online).

  • Click to view Download high-quality image

    Figure 2

    Cell-specific binding and internalization of Apt-ND-ABP. Flow cytometry confirms the specific binding of Apt-ND-ABP to target A549 cells (a), but not control HBE cells (b). (c) CLSM images of A549 cells incubated with Apt-ND-ABP (i) and Lib-ND-ABP (ii) at 37 °C for 2 h. (d) CLSM images of HBE cells incubated with Apt (i) and Apt-ND-ABP (ii) at 37 °C for 2 h. The excitation wavelength of the FITC fluorophore was 488 nm (color online).

  • Click to view Download high-quality image

    Figure 3

    Biomarker-responsive feasibility of Apt-ND-ABP in cells. CLSM images of A549 cells incubated with Apt-ND-ABP (a) and Apt-ND-rd (b) at 37 °C for 2 h. From left to right: fluorescence image of Cy3, FRET fluorescence image of Cy5, and bright field. The 543-nm laser was used for excitation. (c) FRET ratio calculated with ImageJ software accordingly. (d) FRET ratio calculated from the CLSM images of the A549 cells separately transfected with different amounts of BM (black line) and anti-BM (red line) prior to incubation with Apt-ND-ABP (color online).

  • Click to view Download high-quality image

    Figure 4

    Viability of A549 cells treated with Apt-ND-rd, Apt-ND-ABP, Lib-ND-ABP, Apt-control-ABP, and Apt-ND, respectively. Error bars represent the standard deviation of three independent experiments (color online).

Copyright 2019 Science China Press Co., Ltd. 《中国科学》杂志社有限责任公司 版权所有

京ICP备18024590号-1